 buy trade share margin gain
messag continu manag challeng oper environ
drive rx share expens margin via partnership pursuit
tightli manag sg spend evid
appar impact acquir store felt rais
ep estim reflect larger tax benefit lower pt
given compani growth challeng remain buy-rat recogn
difficult consum backdrop mid-sd ebitda growth attract
oper result ep tax rate shown exhibit wba
oper result line expect repres solid growth total sale
rose million estim out-performance concentr
rx portion us segment beat off-set increment gross margin
pressur primarili us fifo gp dollar rose versu forecast sg
dollar grew similar rate adjust ebit ebitda close estim
ebit margin erod basi point basi point us record rx retail share
exchang lower profit big ep beat came tax rate
rx comp ebit margin like soften quarter trade share
margin like intensifi next sever quarter view fuel
complet acquisit last acquir store chang ownership
march four week ahead project timelin detail exhibit
rx top-lin momentum acceler even new specialti busi
cycl margin pressur would also increas given acquir unit oper
well below-averag profit level could also disrupt
integr process margin pressur appear account new ep
smaller inconsequenti frontend busi wba frontend comp declin
nearli second quarter past three declin wors gross
margin continu meaning expand on-going pullback promot spend
gross margin expand basi point past three yearsse exhibit
estim percentag point spread frontend
rx versu frontend weak great concern us
near-term given import synergi captur greater risk
long-term
intermediate-term mid-sd us ebit growth requir continu
increment scale/volum achiev solid mid-sd ebit growth view given
likelihood unrel reimburs pressur limit abil cut
oper cost organ especi increment plan invest
store-level million annual function billion net closur
increment revenu million plu synergi captur believ
abl sustain mid-sd slightli better ebit growth includ
temporari revers recent margin pressur repeat beyond like
elus wont matter view
page analyst certif import disclosur
compani data guggenheim secur llc
page analyst certif import disclosur
pharmaci usa y/i pharmaci intern y/i wholesal y/i elimin y/i cog gross cog gross fifo gross y/i sg y/i expens equiti net incom allianc boot acquisit relat amort cost adjust equiti net incom allianc fifo y/i ebit pharmaci usa fifo y/i ebit pharmaci intern fifo y/i ebit wholesal fifo y/i ebit elimin fifo depreci fifo y/i ebit interest expens incom pre-tax y/i incom tax net incom equiti net y/i net incom equiti method invest y/i interest incom attribut y/i usd drug store
compani data guggenheim secur llc
page analyst certif import disclosur
y/i total number locationsna na na na y/i changena na na na pharmaci y/i rx script equival script number scriptsna na na na number equival front-end y/i fe gross lifo optim gross y/i gross y/i bp acquisit relat amort acquisit relat asset impair store closur optim sg y/i sg y/i bp oper incom ab oper incom ab y/i ebit y/i bp equiti incom fmv warrant gain equiti incom acquisit relat amort oper oper y/i ebit y/i bp usd drug store
exhibit trade share margin intensifi sever quarter
compani data guggenheim secur llc
exhibit frontend rx gross margin move opposit direct recent year
compani data guggenheim secur llc
page analyst certif import disclosur
bp y/i gp y/i gp y/i bp y/i gp y/i fifo fifo bp y/i millionsestimatesactu base guggenheim assumpt drug store
compani data guggenheim secur llc
wba current valuat histor level share trade ebitda
ep compar five-year histor averag consensu ntm ebitda consensu ntm ep
believ wba current valuat remain attract room multipl expans investor gain addit clariti
around potenti improv ebit margin market share gain within segment realiz synergi associ
store acquisit price target base target price-to-earnings ep
ebitda repres upsid includ dividend current level
primari risk thesi compani inabl reduc oper cost within
segment off-set secular gross margin eros would pressur ebit margin intens retail promot price
environ would limit front-end margin expans weaker-than-anticip front-end demand due current econom
environ would make difficult achiev expens leverag
page analyst certif import disclosur
quarterli annual incom statement august fiscal year end
adust equiti net incom allianc boot
fulli adjust equiti net incom allianc boot
sale
adjust net incom equiti net earn
equiti net incom equiti method invest
invest amerisourcebergen
net incom attribut walgreen
compani data guggenheim secur llc
page analyst certif import disclosur
 segment
number locat
total
number script
number equival script
total
gaap equiti incom ab
less fmv warrant gain loss
adjust equiti incom ab
revenu
compani data guggenheim secur llc
page analyst certif import disclosur
 segment
number drug store locat
revenu
compani data guggenheim secur llc
page analyst certif import disclosur
 segment
number distribut center
gaap equiti incom
chang fair market vale warrant
adjust equiti incom amerisourcebergen
revenu
compani data guggenheim secur llc
page analyst certif import disclosur
